Crocs, Inc.
CROX
$123.14
-1.31%
Crocs, Inc. designs, develops, markets, and distributes casual lifestyle footwear and accessories for men, women, and children, operating through two reportable segments — the flagship Crocs Brand (which generates the overwhelming majority of revenue) and the acquired HEYDUDE Brand — within the global apparel, footwear, and accessories industry. The company is best characterized as a mass-market, brand-led footwear platform whose distinctive clog silhouette and proprietary Croslite material give it a highly recognizable, culturally entrenched identity, while its vertically integrated, company-operated direct-to-consumer and wholesale model supports unusually high gross margins for a footwear maker. The current investor narrative is a tug-of-war between a resilient core Crocs franchise and a persistent HEYDUDE overhang: recent coverage highlights analyst upgrades citing brand recovery and attractive valuation alongside a 'struggling HeyDude acquisition' that remains a significant drag, while other commentary frames the stock as a 'dirt cheap' single-digit forward P/E name with identifiable catalysts. Management's credibility now hinges on executing a credible HEYDUDE turnaround, sustaining Crocs Brand momentum in a soft consumer discretionary backdrop, and continuing aggressive share repurchases that shrink the share count and amplify per-share economics.…
CROX
Crocs, Inc.
$123.14
Related headlines
Investment Opinion: Should I buy CROX Today?
Rating: Buy. The core thesis is that CROX offers a rare combination of an 8.2x forward P/E, a 15.2% free cash flow yield, and a 12.7% upside to the $138.75 average analyst target, with all 12 analysts rating the stock a Buy. The market is pricing in stagnation that the cash flow generation does not support.
Supporting evidence is strong: forward EPS of $14.83 against a $123.14 price implies a 8.2x multiple, while the PEG ratio of 0.52 and price-to-sales of 1.15x are well below typical footwear peers. Q2 2026 gross margin of 59.4% and operating margin of 24.2% demonstrate pricing power, and TTM free cash flow of $704.6M funds buybacks that reduced diluted shares from 59.5M to 50.2M over seven quarters. The 48.1% one-year return and 32.6-point relative strength versus SPY confirm that the market has begun to recognize this value.
Key risks that could invalidate the thesis are another HEYDUDE impairment, revenue growth decelerating below 2%, and leverage (1.25x debt-to-equity) limiting flexibility. The rating would upgrade to a stronger Buy if HEYDUDE returns to positive growth and gross margin holds above 59%, and would downgrade to Hold if revenue growth turns negative or if the forward P/E rises above 12x without corresponding earnings growth. On balance, the stock is undervalued relative to its cash generation and analyst targets, though the negative trailing P/E and 25.4x EV/EBITDA mean the valuation case depends on adjusted earnings materializing.
Sign up to view all
CROX 12-Month Price Forecast
The risk/reward is skewed positively: at 8.2x forward EPS with a 15.2% FCF yield and unanimous Buy ratings, the downside to the $95 low target is 22.9% while the upside to the $163 high target is 32.4%. The base case of $130-145 (50% probability) reflects steady execution and a partial re-rating toward the $138.75 average target. However, confidence is medium because revenue growth of 2.6% is weak, leverage is elevated at 1.25x debt-to-equity, and the 1.56 beta means macro shocks could overwhelm company-specific progress. I would upgrade to high confidence if HEYDUDE returns to growth and gross margin exceeds 60%, and downgrade to neutral if revenue growth turns negative or another impairment is announced.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Crocs, Inc.'s 12-month outlook, with a consensus price target around $138.75 and implied upside of +12.7% versus the current price.
Average Target
$138.75
0 analysts
Implied Upside
+12.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$95 - $163
Analyst target range
Bulls vs Bears: CROX Investment Factors
The bull case rests on a compelling valuation (8.2x forward EPS, 0.52 PEG), a 15.2% FCF yield, aggressive buybacks, and a 12.7% analyst target upside, all supported by a 59.4% gross margin core franchise. The bear case centers on the HEYDUDE drag, 2.6% revenue growth, 1.25x debt-to-equity, and a 1.56 beta that amplifies drawdowns. On balance, the evidence currently favors the bulls because the valuation discount is extreme relative to profitability and cash generation, and analyst consensus is uniformly positive. The single most important tension is whether HEYDUDE can be stabilized without further impairments; a credible turnaround would likely trigger multiple expansion toward the $138.75 average target, while another writedown could retest the $95 low target.
Bullish
- Deep value on forward earnings: At $123.14, CROX trades at just 8.2x forward EPS of $14.83, a steep discount to the broader market and to its own historical multiple. The PEG ratio of 0.52 suggests the market is pricing in almost no growth despite a 48.1% one-year total return and 41.6% YTD gain.
- Analyst consensus sees 12.7% upside: All 12 covering analysts rate the stock a Buy (mean recommendation 2.27) with an average target of $138.75 versus the current $123.14, implying 12.7% upside. The high target of $163.00 implies 32.4% upside, and even the low target of $95.00 is only 22.9% below current levels.
- Crocs Brand margin engine intact: Q2 2026 gross margin came in at 59.4% and operating margin at 24.2%, with net income of $204.9M on $1.18B revenue. Trailing twelve-month free cash flow of $704.6M against a $4.64B market cap yields a 15.2% FCF yield, funding aggressive buybacks that shrank diluted shares from 59.5M in Q3 2024 to 50.2M in Q2 2026.
- Relative strength and momentum: CROX has outperformed the S&P 500 by 32.6 percentage points over the past year and 29.7 points YTD, with a 5.5-point relative strength edge in the last month. The stock is up 6.7% in the past month versus SPY's 1.2%, suggesting accumulation despite a 10.2% three-month pullback.
Bearish
- HEYDUDE remains a persistent overhang: The struggling HEYDUDE acquisition is repeatedly cited as a significant drag, and the Q2 2025 impairment drove a $492.3M net loss and -$8.82 EPS. Even after recovery, Q2 2026 revenue growth of only 2.6% YoY shows the core business is not growing fast enough to offset segment weakness.
- Leverage and interest burden: Debt-to-equity stands at 1.25x, and Q2 2026 interest expense of $60.8M consumed roughly 23% of operating income of $285.7M. With a current ratio of 1.27, liquidity is adequate but not ample, leaving limited cushion if consumer discretionary spending weakens.
- High beta amplifies downside: Beta of 1.557 means CROX is roughly 56% more volatile than the market, and the stock has already suffered a 24.25% max drawdown. In a risk-off rotation, the shares could fall disproportionately, especially given the 4.39 short ratio indicating elevated bearish positioning.
- Valuation metrics look distorted: Trailing P/E is negative at -57.0 due to the prior-year impairment, and EV/EBITDA of 25.4x looks expensive versus the 8.2x forward P/E, reflecting the gap between GAAP losses and adjusted earnings. This inconsistency makes the stock hard to screen and can deter institutional buyers.
CROX Technical Analysis
Beta
1.56
1.56x market volatility
Max Drawdown
-24.3%
Largest decline past year
52-Week Range
$73-$141
Price range past year
Annual Return
+48.1%
Cumulative gain past year
| Period | CROX Return | S&P 500 |
|---|---|---|
| 1m | +6.7% | +0.2% |
| 3m | -10.2% | +2.9% |
| 6m | +16.3% | +8.4% |
| 1y | +48.1% | +14.9% |
| ytd | +41.6% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CROX Fundamental Analysis
Quarterly Revenue
$1.2B
2026-06
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
59.4%
Latest Quarter
Free Cash Flow
$704620000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CROX Overvalued?
PE
-57.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~16x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are meaningful. Debt-to-equity of 1.25x and Q2 2026 interest expense of $60.8M against $285.7M operating income show that leverage consumes nearly a quarter of operating profit. Revenue growth of just 2.6% YoY in Q2 2026, combined with a 59.4% gross margin that has compressed from 61.7% in Q2 2025, indicates limited operating leverage and dependence on cost control rather than top-line expansion. The HEYDUDE segment remains a concentrated execution risk; the Q2 2025 impairment produced a $492.3M net loss and -$8.82 EPS, and another writedown would hit both book value and sentiment.
Market and competitive risks are elevated by the stock's high beta of 1.557, which implies roughly 56% more volatility than the S&P 500. The 24.25% max drawdown over the past year shows how quickly sentiment can reverse, and the 4.39 short ratio signals that bearish positioning remains entrenched. Valuation compression is a two-sided risk: while 8.2x forward EPS is cheap, the negative trailing P/E of -57.0 and EV/EBITDA of 25.4x reflect earnings distortion from the impairment, and any re-rating lower would hit a stock that has already fallen 10.2% over three months. Recent news explicitly flags the 'struggling HeyDude acquisition' as an overhang, and a soft consumer discretionary backdrop could pressure the core Crocs Brand.
In a worst-case scenario, HEYDUDE requires another impairment, revenue growth stalls below 2%, and consumer spending weakens, pushing the stock toward the analyst low target of $95.00, or 22.9% below the current $123.14. A retest of the 52-week low of $73.21 would represent a 40.5% decline from current levels, consistent with the 24.25% max drawdown already experienced but amplified by the 1.56 beta. The realistic downside range is therefore -23% to -40%, with the lower end requiring a broad market correction alongside company-specific disappointment.
FAQ
The most severe risk is company-specific: another HEYDUDE impairment, given the $492.3M net loss and -$8.82 EPS in Q2 2025 from the prior writedown. Second is financial leverage, with debt-to-equity at 1.25x and $60.8M quarterly interest expense consuming 23% of operating income. Third is growth stagnation, as Q2 2026 revenue grew only 2.6% YoY, leaving little buffer if consumer discretionary spending weakens. Fourth is market risk from a 1.557 beta, which amplifies drawdowns; the stock has already experienced a 24.25% max drawdown and a 4.39 short ratio indicates persistent bearish positioning. Ranked by severity: HEYDUDE impairment, then revenue deceleration, then leverage, then beta-driven volatility.
The 12-month forecast has three scenarios: a 25% probability bull case of $150-163 (HEYDUDE recovery and multiple expansion to 10-11x forward EPS), a 50% probability base case of $130-145 (steady execution toward the $138.75 analyst average), and a 25% probability bear case of $73-95 (another impairment and consumer weakness). The base case is most likely, assuming revenue growth of 2-4%, gross margin near 58-59%, and no further writedowns. The key assumption is that HEYDUDE stops deteriorating; if it returns to growth, the bull case probability rises, while a negative revenue print would shift weight to the bear case.
CROX appears undervalued on forward earnings: the 8.2x forward P/E and 1.15x price-to-sales are well below typical footwear and apparel peers, and the 0.52 PEG implies the market expects minimal growth. However, the negative trailing P/E of -57.0 and EV/EBITDA of 25.4x reflect the distortion from the Q2 2025 impairment, so the discount is partly justified by earnings quality concerns. The 15.2% FCF yield and 3.58x price-to-book provide a margin of safety, and the 12.7% upside to the $138.75 average target suggests the market is paying a discount rather than a premium. The valuation implies the market expects HEYDUDE to remain a drag and revenue growth to stay near 2%, which creates upside if either assumption proves too pessimistic.
From a risk/reward perspective, CROX is attractive: the stock trades at 8.2x forward EPS of $14.83, offers 12.7% upside to the $138.75 average analyst target, and generates $704.6M in TTM free cash flow, a 15.2% yield on market cap. All 12 analysts rate it a Buy, and the 0.52 PEG suggests growth is not priced in. The biggest downside risk is a HEYDUDE impairment or revenue stall, which could take the stock to the $95 low target (-22.9%) or the $73.21 52-week low (-40.5%). It is a good buy for value-oriented investors with a 12-18 month horizon who can tolerate a 1.56 beta, but less suitable for risk-averse or short-term traders given the 24.25% max drawdown.
CROX is better suited for a medium-to-long-term holding period of at least 12-18 months. The 1.557 beta and 24.25% max drawdown make short-term trading risky, and the 4.39 short ratio can produce sharp squeezes in either direction. The lack of a dividend (0% yield) means total return depends entirely on price appreciation and buybacks, which favor patient holders as diluted shares shrink from 59.5M to 50.2M. Earnings visibility is moderate: Q2 2026 net income of $204.9M and 24.2% operating margin are solid, but the HEYDUDE overhang creates quarterly event risk. A minimum 12-month horizon allows time for the HEYDUDE turnaround to prove out and for the 8.2x forward multiple to re-rate toward the $138.75 target.